Cyclacel Pharmaceuticals Inc.

1.39+0.0100+0.72%Vol 769.58K1Y Perf -78.93%
Jun 27th, 2022 16:00 DELAYED
BID1.35 ASK1.43
Open1.40 Previous Close1.38
Pre-Market- After-Market1.42
 - -  0.03 2.16%
Target Price
20.00 
Analyst Rating
Strong Buy 1.00
Potential %
1.34K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★★     55.30
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
6.08 
Earnings Rating
Strong Buy
Market Cap13.89M 
Earnings Date
10th Aug 2022
Alpha-0.06 Standard Deviation0.23
Beta1.41 

Today's Price Range

1.331.42

52W Range

1.056.64

5 Year PE Ratio Range

-0.8000-1.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-0.71%
1 Month
14.88%
3 Months
-55.87%
6 Months
-63.71%
1 Year
-78.93%
3 Years
-87.14%
5 Years
-98.30%
10 Years
-99.81%

TickerPriceChg.Chg.%
CYCC1.390.01000.72
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Financial StrengthValueIndustryS&P 500US Markets
5.50
5.90
0.00
0.00
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-6 235.30
-6 220.70
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.67-0.4237.31
Q04 2021-0.71-0.5423.94
Q03 2021-0.70-0.5422.86
Q02 2021-0.47-0.56-19.15
Q01 2021-0.45-0.50-11.11
Q04 2020-0.52-1.34-157.69
Q03 2020-0.49-0.474.08
Q02 2020-0.47-0.58-23.40
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.6711.84Positive
9/2022 QR-0.5435.71Positive
12/2022 FY-2.1546.38Positive
12/2023 FY-3.1929.58Positive
Next Report Date10th Aug 2022
Estimated EPS Next Report-0.67
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume769.58K
Shares Outstanding9.99K
Shares Float9.67M
Trades Count2.22K
Dollar Volume1.06M
Avg. Volume488.74K
Avg. Weekly Volume809.78K
Avg. Monthly Volume381.68K
Avg. Quarterly Volume274.76K

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) stock closed at 1.39 per share at the end of the most recent trading day (a 0.72% change compared to the prior day closing price) with a volume of 769.58K shares and market capitalization of 13.89M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cyclacel Pharmaceuticals Inc. CEO is Spiro Rombotis.

The one-year performance of Cyclacel Pharmaceuticals Inc. stock is -78.93%, while year-to-date (YTD) performance is -64.27%. CYCC stock has a five-year performance of -98.3%. Its 52-week range is between 1.05 and 6.64, which gives CYCC stock a 52-week price range ratio of 6.08%

Cyclacel Pharmaceuticals Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.36, a price-to-sale (PS) ratio of 88.29, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -44.53%, a ROC of -47.85% and a ROE of -50.06%. The company’s profit margin is -%, its EBITDA margin is -6 220.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cyclacel Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. Cyclacel Pharmaceuticals Inc.’s next earnings report date is 10th Aug 2022.

The consensus rating of Wall Street analysts for Cyclacel Pharmaceuticals Inc. is Strong Buy (1), with a target price of $20, which is +1 338.85% compared to the current price. The earnings rating for Cyclacel Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cyclacel Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cyclacel Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.50, ATR14 : 0.12, CCI20 : 152.43, Chaikin Money Flow : -0.02, MACD : -0.05, Money Flow Index : 56.17, ROC : 13.11, RSI : 51.68, STOCH (14,3) : 82.50, STOCH RSI : 0.93, UO : 57.81, Williams %R : -17.50), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cyclacel Pharmaceuticals Inc. in the last 12-months were: Samuel L. Barker (Buy at a value of $5 000), Spiro Rombotis (Buy at a value of $18 000)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.

CEO: Spiro Rombotis

Telephone: +1 908 517-7330

Address: 200 Connell Drive, Berkeley Heights 07922, NJ, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

65%35%

TipRanks News for CYCC

Tue, 12 Apr 2022 16:15 GMT Cyclacel Pharmaceuticals (CYCC) Gets a Buy Rating from Brookline Capital Markets

- TipRanks. All rights reserved.

News

Stocktwits